USFDA issues Form 483 with 1 inspectional observation to Cipla's Kurkumbh unit

A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the company's manufacturing facility at Kurkumbh, Maharashtra from April 29, 2024, to May 8, 2024, Cipla said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r6B0LnV
via IFTTT